Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Jiuyang Xu1, Chaolin Huang2, Guohui Fan3,4,5, Zhibo Liu3,4, Lianhan Shang3,4,6, Fei Zhou3,4, Yeming Wang3,4,7, Jiapei Yu1, Luning Yang1, Ke Xie3,7, Zhisheng Huang3,8, Lixue Huang3,7, Xiaoying Gu3,4,5, Hui Li3,4, Yi Zhang3,4, Yimin Wang3,4, Frederick G. Hayden9, Peter W. Horby10, Bin Cao3,4,7,11(), Chen Wang3,4,11,12()
1. Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China 2. Department of Infectious Diseases, Jinyintan Hospital, Wuhan 430030, China 3. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China 4. Institute of Respiratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China 5. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China 6. Beijing University of Chinese Medicine, Beijing 100029, China 7. Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China 8. Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China 9. Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22904, USA 10. Centre for Tropical Medicine and Global Health, University of Oxford, Oxford OX1 2JD, UK 11. Tsinghua University–Peking University Joint Center for Life Sciences, Beijing 100084, China 12. Chinese Academy of Engineering, Beijing 100088, China
The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on anti-hypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P=0.46), ICU admission (20% vs. 28%, P=0.37) or invasive mechanical ventilation (18% vs. 26%, P=0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available.
. [J]. Frontiers of Medicine, 2020, 14(5): 601-612.
Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G. Hayden, Peter W. Horby, Bin Cao, Chen Wang. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front. Med., 2020, 14(5): 601-612.
Duration of viral shedding after illness onsetc (day)
18.0 (15.0, 23.0)
19.0 (15.0, 23.0)
18.0 (14.5, 23.0)
0.8123
Tab.4
Death
ICU admission
IMV
OR (95% CI)
P value
OR (95% CI)
P value
OR (95% CI)
P value
ACEI/ARB
0.73 (0.29–1.82)
0.4994
0.65 (0.25–1.70)
0.3798
0.87 (0.31–2.43)
0.7860
ACEI/ARB (adjusted)a
0.78 (0.32–1.93)
0.5894
0.68 (0.26–1.81)
0.4431
0.92 (0.32–2.63)
0.8796
Tab.5
Univariable OR (95% CI)
P value
Multivariable OR (95% CI)
P value
Age (year)
1.07 (1.03–1.12)
0.0025
1.04 (0.99–1.10)
0.1059
Diabetes
1.76 (0.63–4.91)
0.2820
qSOFA score
4.77 (2.07–10.96)
0.00024
5.41 (2.18–13.48)
0.00028
D-dimer >1 µg/mL
3.43 (1.30–9.02)
0.0125
3.64 (1.10–11.99)
0.0341
Tab.6
1
World Health Organization. Coronavirus disease (COVID-19) outbreak situation. 2020. (accessed May 24, 2020)
2
WJ Guan, ZY Ni, Y Hu, WH Liang, CQ Ou, JX He, L Liu, H Shan, CL Lei, DSC Hui, B Du, LJ Li, G Zeng, KY Yuen, RC Chen, CL Tang, T Wang, PY Chen, J Xiang, SY Li, JL Wang, ZJ Liang, YX Peng, L Wei, Y Liu, YH Hu, P Peng, JM Wang, JY Liu, Z Chen, G Li, ZJ Zheng, SQ Qiu, J Luo, CJ Ye, SY Zhu, NS Zhong; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720 https://doi.org/10.1056/NEJMoa2002032
3
D Wang, B Hu, C Hu, F Zhu, X Liu, J Zhang, B Wang, H Xiang, Z Cheng, Y Xiong, Y Zhao, Y Li, X Wang, Z Peng. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061 https://doi.org/10.1001/jama.2020.1585
4
WJ Guan, WH Liang, Y Zhao, HR Liang, ZS Chen, YM Li, XQ Liu, RC Chen, CL Tang, T Wang, CQ Ou, L Li, PY Chen, L Sang, W Wang, JF Li, CC Li, LM Ou, B Cheng, S Xiong, ZY Ni, J Xiang, Y Hu, L Liu, H Shan, CL Lei, YX Peng, L Wei, Y Liu, YH Hu, P Peng, JM Wang, JY Liu, Z Chen, G Li, ZJ Zheng, SQ Qiu, J Luo, CJ Ye, SY Zhu, LL Cheng, F Ye, SY Li, JP Zheng, NF Zhang, NS Zhong, JX He; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55(5): 2000547 https://doi.org/10.1183/13993003.00547-2020
5
T Chen, D Wu, H Chen, W Yan, D Yang, G Chen, K Ma, D Xu, H Yu, H Wang, T Wang, W Guo, J Chen, C Ding, X Zhang, J Huang, M Han, S Li, X Luo, J Zhao, Q Ning. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091 https://doi.org/10.1136/bmj.m1091
6
F Zhou, T Yu, R Du, G Fan, Y Liu, Z Liu, J Xiang, Y Wang, B Song, X Gu, L Guan, Y Wei, H Li, X Wu, J Xu, S Tu, Y Zhang, H Chen, B Cao. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062 https://doi.org/10.1016/S0140-6736(20)30566-3
7
J Lu, Y Lu, X Wang, X Li, GC Linderman, C Wu, X Cheng, L Mu, H Zhang, J Liu, M Su, H Zhao, ES Spatz, JA Spertus, FA Masoudi, HM Krumholz, L Jiang. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390(10112): 2549–2558 https://doi.org/10.1016/S0140-6736(17)32478-9
8
L Fang, G Karakiulakis, M Roth. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8(4): e21 https://doi.org/10.1016/S2213-2600(20)30116-8
9
Y Liao, X Cheng, Q Zeng, Z Chen, Z Wang, J Yuan, X Wang, Z Zhou, Y Wei, G Cao. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei Province. J Clin Cardiol (Lin Chuang Xin Xue Guan Bing Za Zhi) 2020; 36(3): 201–203 (in Chinese)
10
D Caldeira, J Alarcao, A Vaz-Carneiro, J Costa. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ, 2012; 345: e4260 https://doi.org/10.1136/bmj.e4260
11
EM Mortensen, B Nakashima, J Cornell, LA Copeland, MJ Pugh, A Anzueto, C Good, MI Restrepo, JR Downs, CR Frei, MJ Fine. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55(11): 1466–1473 https://doi.org/10.1093/cid/cis733
12
K Kuba, Y Imai, S Rao, H Gao, F Guo, B Guan, Y Huan, P Yang, Y Zhang, W Deng, L Bao, B Zhang, G Liu, Z Wang, M Chappell, Y Liu, D Zheng, A Leibbrandt, T Wada, AS Slutsky, D Liu, C Qin, C Jiang, JM Penninger. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11(8): 875–879 https://doi.org/10.1038/nm1267
13
Y Yan, Q Liu, N Li, J Du, X Li, C Li, N Jin, C Jiang. Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. Sci China Life Sci 2015; 58(2): 208–211 https://doi.org/10.1007/s11427-015-4814-7
14
M Donoghue, F Hsieh, E Baronas, K Godbout, M Gosselin, N Stagliano, M Donovan, B Woolf, K Robison, R Jeyaseelan, RE Breitbart, S Acton. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000; 87(5): E1–E9 https://doi.org/10.1161/01.RES.87.5.e1
15
SR Tipnis, NM Hooper, R Hyde, E Karran, G Christie, AJ Turner. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275(43): 33238–33243 https://doi.org/10.1074/jbc.M002615200
16
RA Santos, AC Simoes e Silva, C Maric, DM Silva, RP Machado, I de Buhr, S Heringer-Walther, SV Pinheiro, MT Lopes, M Bader, EP Mendes, VS Lemos, MJ Campagnole-Santos, HP Schultheiss, R Speth, T Walther. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100(14): 8258–8263 https://doi.org/10.1073/pnas.1432869100
17
RM Wösten-van Asperen, R Lutter, PA Specht, GN Moll, JB van Woensel, CM van der Loos, H van Goor, J Kamilic, S Florquin, AP Bos. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol 2011; 225(4): 618–627 https://doi.org/10.1002/path.2987
18
W Li, MJ Moore, N Vasilieva, J Sui, SK Wong, MA Berne, M Somasundaran, JL Sullivan, K Luzuriaga, TC Greenough, H Choe, M Farzan. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450–454 https://doi.org/10.1038/nature02145
19
M Letko, A Marzi, V Munster. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5(4): 562–569 https://doi.org/10.1038/s41564-020-0688-y
20
P Zhou, XL Yang, XG Wang, B Hu, L Zhang, W Zhang, HR Si, Y Zhu, B Li, CL Huang, HD Chen, J Chen, Y Luo, H Guo, RD Jiang, MQ Liu, Y Chen, XR Shen, X Wang, XS Zheng, K Zhao, QJ Chen, F Deng, LL Liu, B Yan, FX Zhan, YY Wang, GF Xiao, ZL Shi. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270–273 https://doi.org/10.1038/s41586-020-2012-7
21
R Yan, Y Zhang, Y Li, L Xia, Y Guo, Q Zhou. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367(6485): 1444–1448 https://doi.org/10.1126/science.abb2762
22
I Hamming, W Timens, ML Bulthuis, AT Lely, G Navis, H van Goor. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2): 631–637 https://doi.org/10.1002/path.1570
23
Y Zhao, Z Zhao, Y Wang, Y Zhou, Y Ma, W. ZuoSingle-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. bioRxiv 2020; doi: 10.1101/2020.01.26.919985 https://doi.org/10.1101/2020.01.26.919985
24
PE Gallagher, CM Ferrario, EA Tallant. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008; 295(6): H2373–H2379 https://doi.org/10.1152/ajpheart.00426.2008
25
LM Burrell, J Risvanis, E Kubota, RG Dean, PS MacDonald, S Lu, C Tikellis, SL Grant, RA Lew, AI Smith, ME Cooper, CI Johnston. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26(4): 369–375, discussion 322–364 https://doi.org/10.1093/eurheartj/ehi114
26
AHJ Danser, M Epstein, D Batlle. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 2020; 75(6): 1382–1385 https://doi.org/10.1161/HYPERTENSIONAHA.120.15082
27
Z Huang, J Cao, Y Yao, X Jin, Z Luo, Y Xue, C Zhu, Y Song, Y Wang, Y Zou, J Qian, K Yu, H Gong, J Ge. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med 2020; 8(7): 430 https://doi.org/10.21037/atm.2020.03.229
28
P Zhang, L Zhu, J Cai, F Lei, JJ Qin, J Xie, YM Liu, YC Zhao, X Huang, L Lin, M Xia, MM Chen, X Cheng, X Zhang, D Guo, Y Peng, YX Ji, J Chen, ZG She, Y Wang, Q Xu, R Tan, H Wang, J Lin, P Luo, S Fu, H Cai, P Ye, B Xiao, W Mao, L Liu, Y Yan, M Liu, M Chen, XJ Zhang, X Wang, RM Touyz, J Xia, BH Zhang, X Huang, Y Yuan, L Rohit, PP Liu, H Li. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; [Epub ahead of print] doi: 10.1161/CIRCRESAHA.120.317134 https://doi.org/10.1161/CIRCRESAHA.120.317134
29
N Mehta, A Kalra, AS Nowacki , S Anjewierden, Z Han, P Bhat, AE Carmona-Rubio, M Jacob, G W Procop, S Harrington, A Milinovich, LG Svensson, L Jehi, JB Young, MK Chung.Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; [Epub ahead of print] doi: 10.1001/jamacardio.2020.1855 https://doi.org/10.1001/jamacardio.2020.1855
30
HR Reynolds, S Adhikari, C Pulgarin, AB Troxel, E Iturrate, SB Johnson, A Hausvater, JD Newman, JS Berger, S Bangalore, SD Katz, GI Fishman, D Kunichoff, Y Chen, G Ogedegbe, JS Hochman. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med 2020; [Epub ahead of print] doi: 10.1056/NEJMoa2008975 https://doi.org/10.1056/NEJMoa2008975
31
FJ de Abajo, S Rodríguez-Martín, V Lerma, G Mejía-Abril, M Aguilar, A García-Luque, L Laredo, O Laosa, GA Centeno-Soto, M Ángeles Gálvez, M Puerro, E González-Rojano, L Pedraza, I de Pablo, F Abad-Santos, L Rodríguez-Mañas, M Gil, A Tobías, A Rodríguez-Miguel, D Rodríguez-Puyol, D Barreira-Hernandez, P Zubiaur, E Santos-Molina, E Pintos-Sánchez, M Navares-Gómez, RM Aparicio, V García-Rosado, C Gutiérrez-Ortega, C Pérez, A Ascaso, C Elvira. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet 2020; 395(10238): 1705–1714 https://doi.org/10.1016/S0140-6736(20)31030-8
32
G Mancia, F Rea, M Ludergnani, G Apolone, G Corrao. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med 2020; [Epub ahead of print] doi: 10.1056/NEJMoa2006923 https://doi.org/10.1056/NEJMoa2006923
33
M Singer, CS Deutschman, CW Seymour, M Shankar-Hari, D Annane, M Bauer, R Bellomo, GR Bernard, JD Chiche, CM Coopersmith, RS Hotchkiss, MM Levy, JC Marshall, GS Martin, SM Opal, GD Rubenfeld, T van der Poll, JL Vincent, DC Angus. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315(8): 801–810 https://doi.org/10.1001/jama.2016.0287
34
ADT Force, VM Ranieri, GD Rubenfeld, BT Thompson, ND Ferguson, E Caldwell, E Fan, L Camporota, AS Slutsky. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307(23): 2526–2533
35
KDIGO. Clinical Practice Guideline for Acute Kidney Injury. 2012. (accessed May 24, 2020)
36
C Huang, Y Wang, X Li, L Ren, J Zhao, Y Hu, L Zhang, G Fan, J Xu, X Gu, Z Cheng, T Yu, J Xia, Y Wei, W Wu, X Xie, W Yin, H Li, M Liu, Y Xiao, H Gao, L Guo, J Xie, G Wang, R Jiang, Z Gao, Q Jin, J Wang, B Cao. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506 https://doi.org/10.1016/S0140-6736(20)30183-5
37
M Abe, O Oikawa, K Okada, M Soma. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. J Renin Angiotensin Aldosterone Syst 2015; 16(1): 159–164 https://doi.org/10.1177/1470320314551443
38
M Furuhashi, N Moniwa, T Mita, T Fuseya, S Ishimura, K Ohno, S Shibata, M Tanaka, Y Watanabe, H Akasaka, H Ohnishi, H Yoshida, H Takizawa, S Saitoh, N Ura, K Shimamoto, T Miura. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28(1): 15–21 https://doi.org/10.1093/ajh/hpu086
39
A Soro-Paavonen, D Gordin, C Forsblom, M Rosengard-Barlund, J Waden, L Thorn, N Sandholm, MC Thomas, PH Groop; FinnDiane Study Group. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012; 30(2): 375–383 https://doi.org/10.1097/HJH.0b013e32834f04b6
40
J Liu, H Ji, W Zheng, X Wu, JJ Zhu, AP Arnold, K Sandberg. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ 2010; 1(1): 6 https://doi.org/10.1186/2042-6410-1-6
41
CM Ferrario, J Jessup, PE Gallagher, DB Averill, KB Brosnihan, E Ann Tallant, RD Smith, MC Chappell. Effects of renin-angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors. Kidney Int 2005; 68(5): 2189–2196 https://doi.org/10.1111/j.1523-1755.2005.00675.x
42
S Bunyavanich, A Do, A Vicencio. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020; [Epub ahead of print] doi: 10.1001/jama.2020.8707 https://doi.org/10.1001/jama.2020.8707
43
LR Schouten, AH van Kaam, F Kohse, F Veltkamp, LD Bos, FM de Beer, RT van Hooijdonk, J Horn, M Straat, E Witteveen, GJ Glas, L Wieske, LA van Vught, MA Wiewel, SA Ingelse, B Cortjens, JB van Woensel, AP Bos, T Walther, MJ Schultz, RM Wosten-van Asperen; MARS consortium. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Ann Intensive Care 2019; 9(1): 55 https://doi.org/10.1186/s13613-019-0529-4
44
Y Imai, K Kuba, S Rao, Y Huan, F Guo, B Guan, P Yang, R Sarao, T Wada, H Leong-Poi, MA Crackower, A Fukamizu, CC Hui, L Hein, S Uhlig, AS Slutsky, C Jiang, JM Penninger. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436(7047): 112–116 https://doi.org/10.1038/nature03712
45
M Gheblawi, K Wang, A Viveiros, Q Nguyen, JC Zhong, AJ Turner, MK Raizada, MB Grant, GY Oudit. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020; 126(10): 1456–1474 https://doi.org/10.1161/CIRCRESAHA.120.317015
46
A Gu, SN Farzadeh, YJ Chang, A Kwong, S Lam. Patterns of antihypertensive drug utilization among US Adults with diabetes and comorbid hypertension: the national health and nutrition examination survey 1999–2014. Clin Med Insights Cardiol 2019; 13: 1179546819839418 https://doi.org/10.1177/1179546819839418
47
Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension—A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol 2019; 16(3): 182–241 https://doi.org/DOI: 10.11909/j.issn.1671-5411.2019.03.014
48
J Meng, G Xiao, J Zhang, X He, M Ou, J Bi, R Yang, W Di, Z Wang, Z Li, H Gao, L Liu, G Zhang. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9(1): 757–760 https://doi.org/10.1080/22221751.2020.1746200
49
YD Peng, K Meng, HQ Guan, L Leng, RR Zhu, BY Wang, MA He, LX Cheng, K Huang, QT Zeng. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 2020; 48(0): E004
50
C Bavishi, TM Maddox, FH Messerli. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol 2020; [Epub ahead of print] doi: 10.1001/jamacardio.2020.1282 https://doi.org/10.1001/jamacardio.2020.1282